Skip to main content
. Author manuscript; available in PMC: 2016 Apr 28.
Published in final edited form as: Cell Rep. 2015 Apr 16;11(4):577–591. doi: 10.1016/j.celrep.2015.03.055

Figure 6. IPI145 induces immune stimulatory and angiostatic factors in myeloid cells during antiangiogenic therapy.

Figure 6

(A–D) QPCR analyses of TAM (A), Gr1+Ly6CHi (B) and Gr1+Ly6GHi monocytes (C), and TAN (D) from tumors of RT2 mice treated with sorafenib −/+ IPI145. P values calculated comparing each treatment group to untreated (UT). (E) CD8+ CTLs from tumors of mice treated with sorafenib plus IPI145.(F) Perforin expression in CD8+ CTLs from tumors of mice treated with sorafenib plus IPI145. Dotted lines indicate baseline gene expression in untreated samples. *p≤0.05 versus untreated; #p≤0.05 versus 4 week sorafenib alone. Data from untreated and sorafenib-treated tumors from Figures 2B–2E, 4B–4G are presented in 6A–6F for comparison. Mean±SEM is presented for all quantitation.